<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101369</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 86550-106</org_study_id>
    <nct_id>NCT05101369</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550</brief_title>
  <official_title>An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the absorption, metabolism, and excretion of 86550-106 in healthy males.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the absorption, metabolism, and excretion of a&#xD;
      single oral dose of 400 mg (4x100 mg tablets) of INCB086550 followed by an oral dose solution&#xD;
      of approximately 100 μCi (3.7 MBq) [14C]-INCB086550 and to characterize and determine the&#xD;
      metabolites present in plasma, urine, and, where possible, feces in healthy male participants&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 13, 2021</start_date>
  <completion_date type="Anticipated">March 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total recovery of radioactivity from urine and feces.</measure>
    <time_frame>Approximately 2 weeks</time_frame>
    <description>To determine the route of elimination and mass balance of [14C]-INCB086550 following administration of a single oral dose of 400 mg of INCB086550 followed by an oral dose solution of approximately 100 μCi (3.7 MBq) [14C]-INCB086550.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total radioactive dose in Plasma, Urinary and Fecal Excretion</measure>
    <time_frame>Up to approximately 2 months</time_frame>
    <description>To characterize the metabolic profile and identify circulating and excreted metabolites of INCB086550 following administration of a single oral dose of 400 mg of INCB086550 followed by an oral dose solution of approximately 100 μCi (3.7 MBq) [14C]-INCB086550 using liquid chromatography with mass spectral detection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK for plasma INCB086550: Cmax</measure>
    <time_frame>Pre dose and Post dose on Day 1, Post dose Day 2, post dose Day 3, post dose Day 4, post dose Day 5</time_frame>
    <description>Maximum Observed Plasma Concentration of INCB086550 to evaluate the PK of total radioactivity and parent compound following administration of a single oral dose of 400 mg of INCB086550 followed by an oral dose solution of approximately 100 μCi (3.7 MBq) [14C]-INCB086550.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for plasma INCB086550: tmax</measure>
    <time_frame>Pre dose and Post dose on Day 1, Post dose Day 2, post dose Day 3, post dose Day 4, post dose Day 5</time_frame>
    <description>Time to reach maximum (peak) Plasma concentration of INCB086550</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for plasma INCB086550: AUC0-t</measure>
    <time_frame>Pre dose and Post dose on Day 1, Post dose Day 2, post dose Day 3, post dose Day 4, post dose Day 5</time_frame>
    <description>Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration of INCB086550</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for plasma INCB086550: AUC0-∞</measure>
    <time_frame>Pre dose and Post dose on Day 1, Post dose Day 2, post dose Day 3, post dose Day 4, post dose Day 5</time_frame>
    <description>area under the single-dose plasma concentration-time curve from Hour 0 to infinity of INCB086550</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for plasma INCB086550: t½</measure>
    <time_frame>Pre dose and Post dose on Day 1, Post dose Day 2, post dose Day 3, post dose Day 4, post dose Day 5</time_frame>
    <description>AUC to the end of dosing period of INCB086550</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for plasma INCB086550: λz</measure>
    <time_frame>Pre dose and Post dose on Day 1, Post dose Day 2, post dose Day 3, post dose Day 4, post dose Day 5</time_frame>
    <description>Terminal elimination rate constant of INCB086550</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for plasma INCB086550: CL/F</measure>
    <time_frame>Pre dose and Post dose on Day 1, Post dose Day 2, post dose Day 3, post dose Day 4, post dose Day 5</time_frame>
    <description>Oral dose clearance of INCB086550</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for plasma INCB086550: Vz/F</measure>
    <time_frame>Pre dose and Post dose on Day 1, Post dose Day 2, post dose Day 3, post dose Day 4, post dose Day 5</time_frame>
    <description>Apparent oral dose volume of distribution of INCB086550</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for Urine INCB086550: Ae</measure>
    <time_frame>Pre dose and Post dose daily up to day 11, until study discharge</time_frame>
    <description>Cumulative amount of unchanged drug excreted into the urine. Urine will be collected for the following intervals relative to study treatment administration: -12 to 0 hours (predose void [spot sample] only) and 0 to 6, 6 to 12, and 12 to 24 hours postdose and continuing in 24-hour intervals until discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for urine INCB086550: CLR</measure>
    <time_frame>Pre dose and Post dose daily up to day 11, until study discharge</time_frame>
    <description>Renal clearance of the drug from plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for Urine INCB086550: fe</measure>
    <time_frame>Pre dose and Post dose daily up to day 11, until study discharge</time_frame>
    <description>Fraction of the intravenously administered drug excreted into the urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for whole blood and plasma total radioactivity: Cmax</measure>
    <time_frame>Pre dose and poste dose Day 1, post dose Days 2, 3, 4, 5 and Days 6-11 as needed until study discharge</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for whole blood and plasma total radioactivity: tmax</measure>
    <time_frame>Pre dose and post dose Day 1, post dose Days 2, 3, 4, 5 and Days 6-11 as needed until study discharge</time_frame>
    <description>Time to reach maximum (peak)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for whole blood and plasma total radioactivity: t½</measure>
    <time_frame>Pre dose and post dose Day 1, post dose Days 2, 3, 4, 5 and Days 6-11 as needed until study discharge</time_frame>
    <description>To evaluate the PK of total radioactivity and parent compound following administration of a single oral dose of 400 mg of INCB086550 followed by an oral dose solution of approximately 100 μCi (3.7 MBq) [14C]-INCB086550.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for whole blood and plasma total radioactivity: AUC0-t</measure>
    <time_frame>Pre dose and post dose Day 1, post dose Days 2, 3, 4, 5 and Days 6-11 as needed until study discharge</time_frame>
    <description>Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration of INCB086550</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK for whole blood and plasma total radioactivity: AUC0-∞</measure>
    <time_frame>Pre dose and post dose Day 1, post dose Days 2, 3, 4, 5 and Days 6-11 as needed until study discharge</time_frame>
    <description>To evaluate the PK of total radioactivity and parent compound following administration of a single oral dose of 400 mg of INCB086550 followed by an oral dose solution of approximately 100 μCi (3.7 MBq) [14C]-INCB086550.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs, ECGs, vital signs, and clinical laboratory evaluation.</measure>
    <time_frame>up to approximately 3 months</time_frame>
    <description>To evaluate the safety of a single oral dose of 400 mg of INCB086550 followed by an oral dose solution of approximately 100 μCi (3.7 MBq) [14C]-INCB086550.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>INCB086550</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered INCB086550 orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB086550</intervention_name>
    <description>INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.</description>
    <arm_group_label>INCB086550</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to comprehend and willingness to sign a written ICF for the study.&#xD;
&#xD;
          -  Male healthy adult participants aged 35 to 55 years, inclusive, at the time of&#xD;
             screening.&#xD;
&#xD;
          -  Body mass index between 18.0 and 32.0 kg/m2, inclusive, at the time of screening.&#xD;
&#xD;
          -  No clinically significant findings in screening evaluations (clinical, laboratory,&#xD;
             vital signs, and ECG).&#xD;
&#xD;
          -  Ability to swallow and retain oral medication.&#xD;
&#xD;
          -  Willingness to avoid fathering children based on the criteria below. a. Male&#xD;
             participants with reproductive potential must agree to take appropriate precautions to&#xD;
             avoid fathering children from screening through 90 days (a spermatogenesis cycle)&#xD;
             after the dose of study drug and must refrain from donating sperm during this period.&#xD;
             Permitted methods in preventing pregnancy should be communicated to the participants&#xD;
             and their understanding confirmed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        History of clinically significant respiratory, renal, gastrointestinal, endocrine,&#xD;
        hematopoietic, psychiatric, and/or neurological disease.&#xD;
&#xD;
          -  History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease&#xD;
             or uncontrolled hypertension (systolic blood pressure &gt; 140 mm Hg or diastolic blood&#xD;
             pressure &gt; 90 mmHg at screening, confirmed by repeat testing).&#xD;
&#xD;
          -  History of rheumatologic/autoimmune disorders, except for minor eczema and rosacea.&#xD;
&#xD;
          -  Resting pulse &lt; 40 bpm or &gt; 100 bpm, confirmed by repeat testing at screening.&#xD;
&#xD;
          -  History or presence of an abnormal ECG at screening or predose on Day 1 that, in the&#xD;
             investigator's opinion, is clinically significant. QTcF interval &gt; 450 milliseconds,&#xD;
             QRS interval &gt; 120 milliseconds, and PR interval &gt; 220 milliseconds.&#xD;
&#xD;
          -  Presence of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn's&#xD;
             disease or chronic pancreatitis). Hemoglobin, WBC, platelet, or absolute neutrophil&#xD;
             count that is out of the laboratory's range unless considered clinically insignificant&#xD;
             by the investigator at screening or check-in.&#xD;
&#xD;
          -  Hepatic transaminases (ALT and AST), ALP, or total bilirubin &gt; 1.25 × the&#xD;
             laboratory-defined ULN at screening or check-in, confirmed by repeat testing (except&#xD;
             participants with Gilbert's disease, for which total bilirubin must be ≤ 2.0 × ULN).&#xD;
&#xD;
          -  History of malignancy within 5 years of screening, with the exception of cured basal&#xD;
             cell or squamous cell carcinoma of the skin.&#xD;
&#xD;
          -  Current or recent (within 6 months of screening) clinically significant&#xD;
             gastrointestinal disease or surgery (including cholecystectomy, excluding&#xD;
             appendectomy) that could affect the absorption of study drug.&#xD;
&#xD;
          -  Any major surgery within 6 months of screening.&#xD;
&#xD;
          -  Donation of blood to a blood bank or in a clinical study (except a screening visit)&#xD;
             within 3 months of screening (within 2 weeks for plasma donation).&#xD;
&#xD;
          -  Blood transfusion within 4 weeks of check-in.&#xD;
&#xD;
          -  Chronic or current active infectious disease requiring systemic antibiotic,&#xD;
             antifungal, or antiviral treatment (includes any history of tuberculosis).&#xD;
&#xD;
          -  Positive test for HBV, HCV, or HIV. Participants whose results are compatible with&#xD;
             prior immunization or immunity due to infection for HBV may be included at the&#xD;
             discretion of the investigator.&#xD;
&#xD;
          -  History of alcohol dependency within 3 years of screening.&#xD;
&#xD;
          -  Consumption of alcohol 72 hours before check-in (Day -1) until CRU discharge.&#xD;
&#xD;
          -  Positive breath test for alcohol or positive urine screen for drugs of abuse&#xD;
             (confirmed by repeat) at screening or check-in that are not otherwise explained by&#xD;
             permitted concomitant medications.&#xD;
&#xD;
          -  Current treatment or treatment within 90 days or 5 half-lives (whichever is longer)&#xD;
             prior to dosing in this study with another investigational medication or current&#xD;
             enrollment in another investigational drug study.&#xD;
&#xD;
          -  Participated in any clinical study involving a radiolabeled investigational product&#xD;
             within 12 months prior to check-in.&#xD;
&#xD;
          -  Current treatment or treatment within 30 days or 5 half-lives (whichever is longer)&#xD;
             prior to dosing in this study with any medications known to be an inducer or inhibitor&#xD;
             of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database Program [University&#xD;
             of Washington School of Pharmacy 2002] for prohibited drugs).&#xD;
&#xD;
          -  Consumption of Seville oranges, grapefruit, pomelos, exotic citrus fruits, grapefruit&#xD;
             hybrids, or any fruit juices (including but not limited to juices containing Seville&#xD;
             orange, grapefruit, pomelo, exotic citrus fruits, or grapefruit hybrids) within 72&#xD;
             hours prior to dosing until CRU discharge.&#xD;
&#xD;
          -  Consumption of poppy seeds within 7 days prior to screening and check-in. Consumption&#xD;
             of caffeine- or xanthine-containing products (eg, coffee, tea, cola drinks, and&#xD;
             chocolate) for 72 hours prior to dosing until CRU discharge.&#xD;
&#xD;
          -  History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed&#xD;
             clinically relevant by the investigator.&#xD;
&#xD;
          -  Known hypersensitivity or severe reaction to INCB086550 or any excipients of&#xD;
             INCB086550 (refer to the IB).&#xD;
&#xD;
          -  Inability to undergo venipuncture or tolerate venous access.&#xD;
&#xD;
          -  Inability or unlikeliness of the participant to comply with the dose schedule and&#xD;
             study evaluations, in the opinion of the investigator.&#xD;
&#xD;
          -  History of tobacco- or nicotine-containing product use within 1 month of screening.&#xD;
&#xD;
        Consumption of tobacco- or nicotine-containing products 72 hours before check-in (Day -1)&#xD;
        until CRU discharge is not permitted.&#xD;
&#xD;
          -  Participation in strenuous exercise from 7 days before check-in until CRU discharge.&#xD;
&#xD;
          -  Use of prescription drugs within 14 days of study drug administration or&#xD;
             nonprescription medications/products (including vitamins, minerals, and&#xD;
             phytotherapeutic, herbal, or plant-derived preparations) within 7 days prior to study&#xD;
             drug administration and during the study. However, paracetamol up to 1000 mg Q24H and&#xD;
             ibuprofen up to 600 mg Q24H are permitted.&#xD;
&#xD;
          -  Use or intention to use any COVID-19 vaccine within 30 days prior to Day 1 and through&#xD;
             CRU discharge or ET.&#xD;
&#xD;
          -  Any condition that would, in the investigator's judgment, interfere with full&#xD;
             participation in the study, including administration of study drug and attending&#xD;
             required study visits; pose a significant risk to the participant; or interfere with&#xD;
             interpretation of study data.&#xD;
&#xD;
          -  eGFR &lt; 90 mL/min/1.73 m2 based on the site's preferred formula at screening,&#xD;
             check-in,or both.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy male participants meeting all of the inclusion and none of the exclusion criteria.</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Getsy</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>male only</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

